GlassScriptPhysician profile
Amy Galloway
NPI 1396118618
$1,601.24
in general payments reported to CMS, 2019-2025
14 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.17 · 2022: $12.42 · 2023: $668 · 2024: $342 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.66 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $566.38 | 2023-2025 | Wakix |
| Axsome Therapeutics, INC. | $219.87 | 2023-2025 | Sunosi |
| Inspire Medical Systems, INC. | $145.54 | 2023-2025 | Inspire |
| Zoll Respicardia, INC. | $139.79 | 2024-2025 | Remede System |
| Neurocrine Biosciences, INC. | $139.67 | 2023 | Ingrezza |
| Shield Therapeutics INC | $83.82 | 2025 | |
| Idorsia Pharmaceuticals US INC | $82.31 | 2023 | Quviviq |
| Genentech USA, INC. | $61.52 | 2021 | |
| Electromed, INC. | $59.49 | 2024-2025 | Smartvest |
| Kowa Pharmaceuticals America, INC. | $27.16 | 2022-2023 | Seglentis |
| La Jolla Pharmaceutical Company | $22.96 | 2024 | Xacduro |
| Biohaven Pharmaceuticals, INC. | $20.65 | 2021 | |
| 3b Medical, INC. | $17.34 | 2025 | Luna |
| Avadel Cns Pharmaceuticals, LLC | $14.74 | 2025 | Lumryz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Galloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.